Orca Touchscreen Technologies Ltd. Reports 2018 Annual General and Special Meeting Results
VANCOUVER, British Columbia, June 28, 2018 (GLOBE NEWSWIRE) -- Orca Touchscreen Technologies Ltd. (CSE:OAA) (FSE:6OT) (OTC-Pink:ORTFF) (the “Company” or “Orca”) is pleased to report that all matters submitted to the shareholders of the Company (the “Shareholders”) for approval as set out in the Company’s Notice of Annual General and Special Meeting of Shareholders and Management Information Circular dated May 28, 2018, were approved by the requisite majority of votes cast at the annual general and special meeting of Shareholders held on June 27, 2018 (the “Meeting”).
At the Meeting, the Shareholders: approved the appointment of Manning Elliott LLP, Chartered Professional Accountants as auditors of the Company for the ensuing year at the remuneration to be fixed by the directors; approved the stock option plan of the Company; approved the creation of two (2) new classes of shares designated as “Special Class C Shares” and “Class B Preferred Shares”; and approved the proposed transaction with Cultivator Catalyst Corp. (the “Transaction”). Additionally, the following directors were elected by the Shareholders for the ensuing year, or until the closing of the Transaction: Brian Gusko, Christine Mah, and Nigel Alex Horsley, and the following directors were elected by the Shareholders to serve from the closing of the Transaction until the close of the next annual meeting of Shareholders: Brett James, George Smitherman, Mark Lievonen, and Khurram Malik.
For further information, please contact:
Abbey Abdiye, CFO
Email: abbey@telus.net
Telephone: 604.836.1955
Forward-Looking Information
Completion of the Transaction is subject to a number of conditions, including but not limited to, Canadian Securities Exchange (the “Exchange”) approval. There can be no assurance that the Transaction will be completed as proposed or at all. Certain statements in this release are forward-looking statements, which include completion of the proposed Transaction and regulatory approvals and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, anticipated costs, the ability to achieve its goals, and other factors, many of which are beyond the control of the Company. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Factors that could cause the actual results to differ materially from those in the forward-looking statements include, failure to obtain regulatory approval, the continued availability of capital and financing, and general economic, market or business conditions, changes in legislation and regulations, increase in operating costs, failure of counterparties to perform their contractual obligations, litigation, the loss of key directors, employees, advisors or consultants and fees charged by service providers. The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has in no way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this news release.
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Regeneron Pharmaceuticals' (Nasdaq: REGN) REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
